Liver involvement in children with SARS-COV-2 infection: Two distinct clinical phenotypes caused by the same virus

Adriana Perez MD | Amanda Cantor MD | Bryan Rudolph MD, MPH | Jonathan Miller MD | Debora Kogan-Liberman MD | Qi Gao PhD | Bernardo Da Silva | Kara G. Margolis MD | Nadia Ovchinsky MD, MBA | Mercedes Martinez MD

© 2021 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd

Equal contribution: Adriana Perez and Amanda Cantor.
Corresponding co-authors. Equal contribution: Mercedes Martinez and Nadia Ovchinsky.

Abbreviations: μg/mL, microgram per milliliter; ALI, acute liver injury; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; CDC, centers for disease control and prevention; CI, confidence interval; CK, creatine kinase; CLD, chronic liver disease; COVID-19, coronavirus disease 2019; CRP, C-reactive protein; DILI, drug-induced liver injury; E-ALT, elevated alanine aminotransferase; g/dL, gram per deciliter; ICD-10, international classification of diseases 10th revision; ICU, intensive care unit; IL-6, interleukin 6; INR, international normalized ratio; IQR, interquartile range; IU/L, international units per liter; k/μL, kilo per microliter; LDH, lactate dehydrogenase; mg/dL, milligram per deciliter; mg/L, milligram per liter; MIS-C, multisystem inflammatory disease in children; mm3, cubic millimeter; NAFLD, non-alcoholic fatty liver disease; ng/mL, nanogram per milliliter; NYC, New York City; OR, odds ratio; pg/mL, picogram per milliliter; pro-BNP, pro-B type natriuretic peptide; SARS-CoV-2, severe acute respiratory syndrome coronavirus-2; SD, standard deviation; U/L, units per liter; ULN, upper limit of normal.

Abstract

Background and Aims: Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) associated acute liver injury (ALI) has been linked to poor outcomes in adults. Here we compare characteristics in children with elevated ALT (E-ALT) in two distinct manifestations of the infection, multisystem inflammatory syndrome-children (MIS-C) and coronavirus disease 2019 (COVID-19).

Methods: This is a retrospective study of patients ≤21 years of age with positive for SARS-CoV-2 PCR. E-ALT was defined as alanine aminotransferase (ALT) > 40 U/L. Bivariate analysis and multivariable logistic regression were obtained to describe differences in children with and without E-ALT in COVID-19 and MIS-C.

Results: E-ALT was detected in 36% of the 291 patients; 31% with COVID-19, and 51% with MIS-C. E-ALT in COVID-19 was associated with obesity (P < .001), immunocompromised status (P = .04), and chronic liver disease (P = .01). In the regression models, E-ALT in COVID-19 was associated with higher C-reactive protein (OR 1.08, P = .01) after adjusting for common independent predictors. Children with E-ALT and MIS-C were more often boys (P = .001), Hispanic (P = .04), or Black (P < .001). In MIS-C, male gender (OR 5.3, P = .02) and Black race (OR 4.4, P = .04) were associated with increased odds of E-ALT. Children with E-ALT in both cohorts had significantly higher multiorgan dysfunction, longer hospitalization, and ICU stay. Children with MIS-C had 2.3-fold increased risk of E-ALT compared to COVID-19. No association was found between E-ALT and mortality.
1 | INTRODUCTION

The clinical manifestations of severe acute respiratory syndrome (SARS)-associated coronavirus 2 (SARS-CoV-2) infection are typically mild in children. However, severe symptoms and even deaths from Coronavirus Disease 2019 (COVID-19) can occur. A separate pediatric-specific clinical presentation arises in the form of an entity termed Multisystem Inflammatory Syndrome (MIS-C), characterized by a persistent acute febrile illness progressing to multiorgan dysfunction.

The prevalence of acute liver injury (ALI) in adult patients with COVID-19 ranges from 15%-78%, with most studies reporting 20%-30% among hospitalized patients. ALI, defined as an elevation in aminotransferases and typically presenting as hepatocellular histological injury with mild acute cholestasis, has been documented in adults and children with SARS-CoV-2 infection. Most adult patients experience transient mild to moderate elevation of liver enzymes. Severe ALI (alanine aminotransferase [ALT] values 5x above the upper limit of normal [ULN]) was reported to correlate with disease severity and poor outcomes in adults, including death.

In contrast, less is known about the association between elevated ALT (E-ALT) and disease severity in children with SARS-CoV-2. In this study, we looked at elevations in ALT (E-ALT), as a surrogate marker for liver injury, similar to what has been done in adult studies. We previously published a focused description of the association of hepatitis with disease severity in a cohort of 44 patients with MIS-C included within this report. We now further expand the scope of understanding of liver involvement in two clinical presentations of SARS-CoV-2. We provide critical data on its associating factors, epidemiology, and their contribution to the consequences of elevated ALT in children with COVID-19 versus MIS-C.

2 | METHODS

In this retrospective study, we included patients ≤21 years old evaluated between March 14, 2020 and June 30, 2020, in the inpatient or outpatient clinical setting of two large children’s hospitals in New York City (Morgan Stanley Children's Hospital of New York-Presbyterian and Children's Hospital at Montefiore). The Institutional Review Board approved this study at both centers. All research was conducted following the Declaration of Helsinki guidelines of good practice.

Patients were identified by the international classification of diseases 10th revision (ICD-10) code for a positive COVID-19 test (U07.1) and/or by an institutional COVID-19 or MIS-C database. Only participants with confirmed SARS-CoV-2 infection with detection of the virus via nasal swab-derived real-time reverse polymerase chain reaction were included in the COVID-19 cohort. MIS-C was defined by the modified criteria of the Centers for Disease Control and Prevention (CDC) (see supplement). We excluded children without liver tests.

Clinical, demographic, laboratory, and anthropometric data were collected. We have defined E-ALT as a peak elevation of ALT >40 U/L, as these values were reported to fall above the 97th percentile for all ages and both sexes in a large cohort of healthy children. Measures of hepatic synthetic dysfunction, such as international normalized ratio (INR) and bilirubin, were not included in this definition, given the multifactorial reasons for abnormal values in this clinical setting. Each patient’s medical records were manually reviewed for the presence of comorbidities.

E-ALT was further categorized as mild to moderate (ALT > 40 ≤ 200 U/L) and severe (ALT > 200 U/L). Due to the small number of patients with severely E-ALT and unchanged statistical significance when combined with mild to moderate elevations in ALT, all analyses were subsequently dichotomized as E-ALT present...
(ALT > 40 U/L) or absent (ALT ≤ 40 U/L) within each cohort. We also evaluated AST, bilirubin, albumin, and INR values. Obesity was defined as body mass index (BMI) above 95th percentile and/or BMI ≥ 30 kg/m² as applicable. An immunocompromised state was defined by the presence of malignancy requiring chemotherapy or radiation, recipients of bone marrow or solid organ transplant, or among patients receiving other immunosuppressive therapy or biologics including those with inflammatory bowel disease.

Student’s t-test or Mann–Whitney U-test was performed for continuous variables. Chi-square or Fisher’s exact test was used for categorical variables to identify differences between the presence or absence of E-ALT within each cohort (COVID-19 and MIS-C) and to compare the differences between them. Variables were presented as frequency (percentage), mean with standard deviation (SD), or median with interquartile range (IQR), as appropriate.

Multivariable logistic regression was used to examine the potential risk factors for E-ALT by cohort (COVID-19 and MIS-C) and for the combined data set. Clinically significant variables and/or those with \( P < .25 \) in bivariate analysis were selected. Due to the small sample size in each cohort, the association between the potential risk factors and E-ALT was tested sequentially, while controlling for age, gender, and race in each model, as well as for other predictors. Backward variable selection was used to compare E-ALT in MIS-C to E-ALT in COVID-19 until all variables were significant, while controlling for age, gender, and race. \( P \)-values < 0.05 were considered statistically significant. All analyses were performed using SAS 9.4.

### 3 | RESULTS

A total of 291 patients were included in the study: 220 (76%) and 71 (24%) were diagnosed with COVID-19 and MIS-C respectively (Figure 1). Elevated ALT was detected in 36% \( (n = 105) \) of all children, 31% \( (n = 69) \) of children with COVID-19, and 51% \( (n = 36) \) of children with MIS-C. Severe injury was noted in 8% and 4% of children with COVID-19 and MIS-C, respectively. One child with MIS-C developed acute liver failure and recovered.

**FIGURE 1** Flow-chart of study cohort demonstrating the differences of ALI in the COVID-19 and MIS-C cohorts; A total of 291 patients were included in the study: 220 (76%) and 71 (24%) were diagnosed with COVID-19 and MIS-C, respectively. ALI was detected in 31% \( (n = 69) \) of children with COVID-19 and 51% \( (n = 36) \) of children with MIS-C. Severe injury defined as ALT > 200 U/L was noted in 8% of children with COVID-19 and 4% of children with MIS-C, respectively. Abbreviations: ALI, acute liver injury; ALT, alanine aminotransferase; COVID-19, Coronavirus disease 2019; MIS-C, system inflammatory syndrome in children.
3.1 | Liver involvement in COVID-19

Children with E-ALT were significantly older, with a median age of 16 vs 11 years ($P = .001$). No differences were observed in race, gender, or ethnicity. E-ALT was associated with obesity ($P < .001$), immunocompromised status ($P = .04$), presence of any malignancy ($P = .01$), and chronic liver disease (CLD) ($P = .01$). Underlying CLD was present in 13% of children with E-ALT. The etiologies of CLD in patients in whom prior medical history could be discerned were non-alcoholic fatty liver disease (NAFLD) (six patients), biliary atresia (1), liver transplant recipient (1), and glycogenic hepatopathy (1) (Tables 1, 2; Tables S1 and S2).

3.2 | Liver involvement in MIS-C

Children with E-ALT were also significantly older, with a median age of 9.5 vs 6 years ($P = .01$). E-ALT was associated with Black race ($P = .01$) and male gender ($P = .001$). Most children had no prior medical history and no differences in BMI were noted (Tables 1, 2; Tables S3).

3.3 | Liver involvement in MIS-C compared to COVID-19

Liver involvement in both cohorts was characterized by statistically significant elevation of median ALT above 2x ULN with mild cholestasis. MIS-C hepatitis was associated with decreased albumin (median 2.7, $P < .001$) and thrombocytopenia (mean 134, $P = .01$). Children with E-ALT and MIS-C were more frequently Hispanic ($P < .001$) and of Black race ($P < .001$). Cardiac dysfunction ($P < .001$), kidney injury ($P = .01$), elevated troponin ($P = .03$), higher pro-B natriuretic peptide ($P < .001$), higher median D-dimer levels ($P = .01$), and higher peak interleukin-6 ($P = .04$) were more frequently recorded in the MIS-C cohort with E-ALT (Tables 1, 2; Tables S4).

Children with E-ALT in both cohorts had a severe disease course with a greater prevalence of multiorgan dysfunction ($P = .001$ in both cohorts), respiratory failure ($P = .001$ and 0.01 in COVID-19 and MIS-C, respectively), longer hospitalization ($P < .001$ and .001), and longer ICU stay ($P = .01$ and 0.04). No significant association was found between E-ALT and mortality in COVID-19 (see Table S6 for details), and no deaths were recorded in the MIS-C cohort. In multivariable analysis, E-ALT in the COVID-19 cohort was associated with an increase in c-reactive protein (CRP) level (OR 1.08 with 95% confidence interval [CI] [1.03-1.15]) after adjustment for age, gender, race, obesity, CLD, and ICU admission (Table 3). In the MIS-C cohort, male gender and Black race were associated with more than 5- and 4-fold increased E-ALT odds, respectively, when adjusted for age and CRP (Table 3). The association with gender was consistent in all multivariable regression models; Black race was also associated with E-ALT when adjusted for obesity but did not reach statistical significance in other models (Table S5).

Children with MIS-C had 2.3x increased odds of elevated ALT levels than children with COVID-19 after adjusting for age and race.

4 | DISCUSSION

In our study, 36% of children developed E-ALT, which was also associated with mild cholestasis. Irrespective of their SARS-CoV-2 manifestations, those with E-ALT experienced more severe clinical courses. The association of E-ALT coupled with severe COVID-19 has been documented in the adult literature but only scarcely in pediatric literature. The E-ALT mechanism in SARS-CoV-2 is not fully understood, but under investigation are an effect of viral lesions in hepatic/cholangiocyte cells, inflammatory damage, hypoxic/shock-related circulatory compromise, endothelial dysfunction, microthrombi formation, and drug toxicity. The direct viral cytopathic effect in the pathophysiology of E-ALT via the cell receptors for angiotensin-converting enzyme II and transmembrane protease serine 2, invoked in the transmission of SARS-CoV-2, is supported by the demonstration of SARS-CoV-2 in the liver parenchyma in patients with higher enzyme elevation.

As previously reported, children with E-ALT in the COVID-19 cohort more frequently carried an underlying medical condition such as immunocompromised state (including malignancy), or CLD, significantly contrasting with those with E-ALT in MIS-C. In our study, although children with MIS-C had >2x higher odds of any degree of elevation in ALT levels compared to children with COVID-19 (51% vs 31%), severe elevation, defined as ALT >200 U/L was observed at a higher frequency in children with COVID-19 (8% vs 4%) (Figure 1). A possible explanation of why a higher percentage of children with COVID-19 (as opposed to MIS-C) had a severe elevation (ALT > 200 U/L) could be due to the significantly greater number of comorbidities that the COVID-19 population possessed that can contribute to hepatitis, including obesity. It mirrors prior observations that MIS-C affects previously healthy children but SARS-Cov2 can induce a severe cytokine storm with a hyperinflammatory state with either disease entity. The pathophysiology of organ damage is unknown, although differences in cytokines and autoantibodies profiles have been identified.

Obesity was present in both cohorts, albeit significantly more prevalent in children with E-ALT in COVID-19. Among them, only six children were previously diagnosed with NAFLD. We cannot exclude the possibility of a higher prevalence of NAFLD within this cohort due to our retrospective design limitations. It has been proposed that patients with NAFLD may be susceptible to a worsening viral oxidative stress when infected with a hepatotoxic virus.

It is worth noting that the three patients who died of COVID-19 and developed E-ALT and the single patient in the MIS-C cohort who developed acute liver failure were obese (Table S6). Adult literature also highlights the association between clinical course severity and obesity in COVID-19. It further implies that increased...
morbidity may be due to obesity-related impact on cytokine dysfunction or impaired immune response in leptin resistance, raising concerns that obesity influences disease behavior. This observation is particularly relevant given the increasing prevalence of obesity in our children and is an essential practical point for the bedside physician.

### TABLE 1  Patient characteristics in children with COVID-19 and MIS-C with and without Elevated ALT

|                       | COVID-19 | MIS-C | COVID-19 vs MIS-C* |
|-----------------------|----------|-------|--------------------|
|                       | ALT ≤ 40 U/L | ALT > 40 U/L | P-value | ALT ≤ 40 U/L | ALT > 40 U/L | P-value | P-value |
| Demographics          |          |       |                    |
| Age (years), median   | 11 (2-17)| 16 (8-20) | 0.001 | 6 (2-10) | 9.5 (6.0-13.5) | 0.01 | 0.01 |
| (IQR)                 |          |       |                    |
| Male sex, n (%)       | 87 (58) | 49 (71) | 0.06 | 11 (31) | 25 (69) | 0.001 | 0.87 |
| Hispanic ethnicity, n (%) | 50 (43) | 19 (31) | 0.13 | 14 (48) | 16 (53) | 0.69 | 0.04 |
| Black race, n (%)     | 26 (26) | 7 (14) | 0.08 | 6 (24) | 13 (59) | 0.01 | <0.001 |
| Comorbidities         |          |       |                    |
| Asthma, n (%)         | 25 (17) | 17 (25) | 0.16 | 2 (6) | 6 (17) | 0.26 | 0.35 |
| Chronic liver disease, n (%) | 4 (3) | 9 (13) | 0.01 | 0 | 0 | - | 0.03 |
| Congenital heart disease, n (%) | 10 (7) | 2 (3) | 0.35 | 0 | 0 | - | 0.54 |
| Diabetes mellitus, n (%) | 11 (7) | 7 (10) | 0.48 | 0 | 1 (2.8) | 1.00 | 0.26 |
| Immunosuppression, n (%) | 9 (6) | 11 (16) | 0.02 | 0 | 0 | - | 0.01 |
| Malignancy, n (%)     | 5 (3) | 10 (15) | 0.01 | 0 | 0 | - | 0.01 |
| Obesity, n (%)        | 28 (23) | 34 (54) | <0.001 | 6 (19) | 11 (31) | 0.26 | 0.02 |
| Clinical course characteristics |          |       |                    |
| ICU admission, n (%)  | 28 (19) | 24 (35) | 0.01 | 15 (43) | 23 (64) | 0.08 | 0.01 |
| ICU length of stay (days)b | 2.1 (±6.8) | 5.3 (±12.1) | 0.01 | 1.8 (±2.6) | 3.6 (±3.9) | 0.04 | 0.08 |
| Hospital length of stay (days)b | 6.1 (±12.1) | 15.8 (±27.1) | <0.001 | 5 (3-7) | 8 (5-10) | 0.001 | 0.48 |
| Multiorgan dysfunction, n (%) | 6 (4) | 12 (17) | 0.001 | 5 (14) | 11 (31) | 0.10 | 0.12 |
| Respiratory failure, n (%) | 18 (12) | 21 (30) | 0.001 | 1 (3) | 11 (31) | 0.01 | 0.99 |
| Cardiac dysfunction, n (%) | 13 (9) | 12 (17) | 0.06 | 16 (46) | 20 (56) | 0.41 | <0.001 |
| Kidney dysfunction, n (%) | 12 (8) | 5 (7) | 0.85 | 5 (14) | 10 (28) | 0.16 | 0.01 |
| Death, n (%)          | 4 (3) | 3 (4) | 0.68 | 0 | 0 | - | 0.55 |
| Therapeutic agent use |          |       |                    |
| Remdesivir, n (%)     | 7 (5) | 7 (10) | 0.23 | 0 | 3 (8) | 0.24 | 1.0 |
| Systemic steroids, n (%) | 17 (11) | 23 (33) | <0.001 | 26 (74) | 29 (81) | 0.53 | <0.001 |
| Antibiotics, n (%)    | 44 (51) | 31 (76) | 0.01 | 8 (80) | 15 (88) | 0.61 | 0.48 |

Abbreviations: ICU, intensive care unit; IQR, interquartile ranges; SD, standard deviation.

For additional variables, please see supplemental tables.

*b compares children with elevated ALT values defined as ALT >40 U/L in COVID-19 vs MIS-C.

Values reported as mean (±SD).
and Hispanics, have been noted, but these observations are based on limited data. Population-based data from MIS-C in NYC also concluded a disproportionate MIS-C burden among Black and Hispanic children. It is unclear whether this finding represents an actual phenomenon or skewness due to missing race/ethnicity data for most confirmed, non-hospitalized, and nonfatal cases. We did not identify any racial differences predisposing children to E-ALT in COVID-19. Black and Hispanic children with MIS-C were more frequently affected by E-ALT compared to those with COVID-19. Furthermore, children of Black race may be disproportionately impaired by E-ALT in MIS-C.

### TABLE 2  Laboratory characteristics in children with COVID-19 and MIS-C with and without elevated ALT

|                      | COVID-19 |            |            | MIS-C |            |            | COVID-19 vs MIS-C |
|----------------------|----------|------------|------------|-------|------------|------------|------------------|
|                      | ALT ≤ 40 U/L | ALT > 40 U/L | P-value | ALT ≤ 40 U/L | ALT > 40 U/L | P-value |                  |
| Liver tests          |          |            |            |       |            |            |                  |
| Median (IQR)         |          |            |            |       |            |            |                  |
| ALT (U/L), peak      | 19 (15-25) | 98 (58-197) | <0.001    | 23 (15-31) | 77 (58-117) | <0.001    | 0.16             |
| AST (U/L), peak      | 31 (21-43) | 78 (53-137) | <0.001    | 30 (26-34) | 88 (62-124) | <0.001    | 0.84             |
| Total bilirubin (mg/dL), peak | 0.4 (0.2-0.8) | 0.6 (0.4-1.0) | 0.001 | 0.4 (0.3-0.6) | 0.8 (0.6-1.8) | <0.001 | 0.02 |
| Albumin (g/dL), nadir | 4.3 (3.7-4.8) | 3.5 (2.9-4.2) | <0.001 | 3.3 (2.5-4.0) | 2.7 (2.3-3.2) | 0.02 | <0.001 |
| Coagulation tests    |          |            |            |       |            |            |                  |
| Median (IQR)         |          |            |            |       |            |            |                  |
| INR, peak n = 127    | 1.2 (1.1-1.3) | 1.2 (1.1-1.3) | 0.51 | 1.2 (1.1-1.4) | 1.3 (1.2-1.4) | 0.23 | 0.01             |
| D Dimer (µg/mL), peak | 1.2 (0.5-3.2) | 2.2 (0.9-6.3) | 0.05 | 3.0 (1.5-4.5) | 4.8 (3.2-15.3) | 0.01 | 0.01             |
| Complete blood count |          |            |            |       |            |            |                  |
| Mean (±SD)           |          |            |            |       |            |            |                  |
| White blood cell count (10³/mm³), peak | 11.0 (±6.5) | 14.3 (±14.5) | 0.02 | 16.4 (±9.7) | 21.1 (±13.8) | 0.11 | 0.02             |
| Acute lymphocytic count (cells/mm³), nadir | 2.295 (±1.641) | 1.380 (±1.150) | <0.01 | 2.005 (±1967) | 1.382 (±1234) | 0.33 | 0.99             |
| Platelet count (10³/mm³), peak | 250 (±129) | 210 (±120) | 0.03 | 235 (±136) | 134 (±96) | 0.001 | 0.01             |
| Inflammatory markers |          |            |            |       |            |            |                  |
| Median (IQR)         |          |            |            |       |            |            |                  |
| CRP (mg/dL), peak    | 1.4 (0.5-5.7) | 13.6 (3.6-23.4) | <0.001 | 14.0 (2.9-25.2) | 19.0 (6.0-30.0) | 0.07 | 0.06             |
| Ferritin (ng/mL), peak | 144 (71-382) | 1208 (368-2629) | <0.001 | 344 (171-531) | 759 (508-1641) | <0.001 | 0.69             |
| IL 6 (pg/mL), peak   | 22.9 (7.3-78.7) | 61.4 (9.0-315.0) | 0.30 | 213.1 (31.0-315.0) | 234.6 (86.6-315.0) | 0.51 | 0.04             |
| LDH (U/L), peak      | 287 (217-386) | 464 (353-738) | <0.001 | 315 (288-409) | 370 (300-482) | 0.07 | 0.19             |
| Other tests          |          |            |            |       |            |            |                  |
| Median (IQR)         |          |            |            |       |            |            |                  |
| CK (IU/L), peak      | 138 (77-226) | 223 (100-662) | 0.12 | 120 (67-168) | 280 (78-983) | 0.18 | 0.93             |

Note: Clinically relevant and significant values depicted.

Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; CK, creatine kinase; CRP, C-reactive protein; g/dL, gram per deciliter; ICU, intensive care unit; IL 6, interleukin 6; INR, international normalized ratio; IU/L, international units per liter; k/uL, kilo per microliter; LDH, lactate dehydrogenase; mg/dL, milligram per deciliter; mg/L, milligrams per liter; mm³, cubic millimeter; ng/mL, nanogram per milliliter; pg/ml, picograms per milliliter; U/L, unit per liter; µg/mL, microgram per milliliter.

For additional variables, please see supplemental tables.

*a compares children with elevated ALT defined as ALT > 40 U/L in COVID-19 vs MIS-C.
We cannot exclude that some children with COVID-19 or MIS-C had additional liver insults including ischemia, congestion, and/or drug-induced liver injury (DILI). No differences in antibiotics or Remdesivir use between children with and without E-ALT in both cohorts were observed, making DILI less probable.

There are multiple strengths to our study. We have analyzed one of the largest North American cohort of pediatric patients with E-ALT in MIS-C, and COVID-19 admitted to two tertiary care centers in a former epicenter of the pandemic. Our centers follow similar protocols for diagnosis, treatment, and management and serve diverse patient populations, allowing us to generalize the laboratory values and scrutinize patients' disease courses across both centers.

Our study cohort is significantly smaller than those of adult studies, limiting our ability to model all predictors of E-ALT used in multivariate analyses of adult populations. Additionally, we were unable to evaluate the full impact of CLD in the full etiology of elevated ALT levels due to lack of preadmission laboratory tests and imaging. Our study, similarly, to others, is burdened by missing race/ethnicity data due to retrospective design.

In conclusion, liver involvement associated with SARS-CoV-2 infection typically leads to a temporary moderate elevation of liver tests without significant hepatic synthetic function impairment. Patients with SARS-CoV-2 infection and E-ALT are at risk of a more severe disease course including longer hospitalization and ICU stays. Children require careful management and monitoring throughout their hospitalization and thereafter to establish resolution of elevated ALT values. Further studies need to provide mechanistic insights into the pathophysiology of underlying liver injury in both conditions.

**CONFLICTS OF INTEREST**

The authors declare no conflict of interest related to this study.

**DATA AVAILABILITY STATEMENT**

The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.

**ORCID**

Mercedes Martinez https://orcid.org/0000-0001-6128-0155

**REFERENCES**

1. Bialek S, Gierke R, Hughes M, McNamara LA, Piilhivli T, Skoff T. Coronavirus disease 2019 in children — United States, February 12–April 2, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(14):422-426.
2. Lu X, Zhang L, Du H, et al. SARS-CoV-2 infection in children. N Engl J Med. 2020;382(17):1663-1665.
3. Ludvigsson JF. Systematic review of COVID-19 in children shows milder cases and a better prognosis than adults. Acta Paediatr. 2020;109(6):1088-1095.
4. Zachariah P, Johnson CL, Halabi KC, et al. Epidemiology, clinical features, and disease severity in patients with coronavirus disease 2019 (COVID-19) in a children's hospital in New York City, New York. JAMA Pediatr. 2020;174(10):e202430.
5. Prevention CfDaC. Coronavirus disease 2019 (COVID-19). CDC COVID Data Tracker. [cited 2020 06/19/2020]. Available from: https://covid.cdc.gov/covid-data-tracker/#cases_casesper100klast7days
6. Rajapakse N, Dixit D. Human and novel coronavirus infections in children: a review. Paediatr Int Child Health. 2020;41:1-20.
7. Miller J, Cantor A, Zachariah P, Ahn D, Martinez M, Margolis KG. Gastrointestinal symptoms as a major presentation component of a novel multisystem inflammatory syndrome in children that is related to coronavirus disease 2019: A single center experience of 44 cases. Gastroenterol. 2020;159(4):1571-1574.
8. Shekerdemian LS, Mahmood NR, Wolfe KK, et al. Characteristics and outcomes of children with coronavirus disease 2019 (COVID-19) infection admitted to US and Canadian pediatric intensive care units. JAMA Pediatr. 2020;174(9):868-873.
9. Prevention CfDaC. National Center for Health Statistics. Weekly updates by select demographic and geographic characteristics. Provisional death counts for coronavirus disease 2019 (COVID-19). 2020 [cited 2020 12/02/2020]. Available from: https://www.cdc.gov/nchs/nvss/vsr/covid_weekly/#AgeAndSex
10. Verdoni L, Mazza A, Gervasoni A, et al. An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study. Lancet. 2020;395(10239):1771-1778.
11. Belhadjer Z, Méot M, Bajolle F, et al. Acute heart failure in multi-system inflammatory syndrome in children associated with severe acute respiratory syndrome coronavirus 2 infection (MIS-C): a multi-institutional study from New York City. J Pediatr. 2020;224:24-29.
12. Xu L, Liu J, Lu M, Yang D, Zheng X. Liver injury during highly pathogenic SARS-CoV-2 epidemic: an observational cohort study. Pediatr Transplant. 2020;24(8):e13778.
13. Phipps MM, Barraza LH, LaSota ED, et al. Acute liver injury in SARS-CoV-2 hepatitis early after liver transplantation. Pediatr Transplant. 2020;24(8):e13778.
14. Lee IC, Huo TI, Huang YH. Gastrointestinal and liver manifestations of severe acute respiratory syndrome coronavirus 2 infection as cholestatic jaundice in two healthy adolescents. J Pediatr. 2020;226:278-280.
15. Cai Q, Huang D, Yu H, et al. COVID-19: abnormal liver function tests. J Hepatol. 2020;73(3):566-574.
16. Perez A, Kogan-Liberman D, Sheflin-Findling S, Raizner A, Ahuja KL, Ovchinsky N. Presentation of severe acute respiratory syndrome coronavirus 2 infection as cholestatic jaundice in two healthy adolescents. J Pediatr. 2020;226:278-280.
17. Cantor A, Miller J, Zachariah P, DaSilva B, Margolis K, Martinez M. Acute hepatitis is a prominent presentation of the multisystem inflammatory syndrome in children: a single-center report. Hepatol. 2020;72(5):1522-1527.
18. Prevention CfDaC. Multisystem Inflammatory Syndrome (MIS-C) 2020. [cited 2020 12/09/2020]. Available from: https://www.cdc.gov/mis-c/hcp/
19. Prevention CfDaC. Multisystem Inflammatory Syndrome (MIS-C) 2020. [cited 2020 12/09/2020]. Available from: https://www.cdc.gov/mis-c/hcp/
20. Bussler S, Vogel M, Pietzner D, et al. New pediatric percentiles of liver enzyme serum levels (alanine aminotransferase, aspartate aminotransferase, \( \gamma \)-glutamyltransferase): effects of age, sex, body mass index, and pubertal stage. Hepatol. 2018;68(4):1319-1330.
21. Kaushik S, Aydin SI, Derespina KR, et al. Multisystem inflammatory syndrome in children associated with severe acute respiratory syndrome coronavirus 2 infection (MIS-C): a multi-institutional study from New York City. J Pediatr. 2020;224:24-29.
22. Harrison AG, Lin T, Wang P. Mechanisms of SARS-CoV-2 transmission and pathogenesis. Trends Immunol. 2020;41(12):1100-1115.
23. Chen H, Zou T-H, Xuan B, et al. Single cell transcriptome revealed SARS-CoV-2 entry genes enriched in colon tissues and associated with coronavirus infection and cytokine production. Signal Transduct Target Ther. 2020;5(1):121.
24. Cai Q, Huang D, Yu H, et al. COVID-19 and liver damage: narrative review and proposed clinical protocol for critically ill pediatric patients. Clinics (Sao Paulo). 2020;75:e2250.
25. Lagana SM, Kudose S, Iuga AC, et al. Hepatic pathology in patients dying of COVID-19: a series of 40 cases including clinical, histologic, and virologic data. Mod Pathol. 2020;33(11):2147-2155.
26. Heinz N, Griesemer A, Kinney J, et al. A case of an infant with SARS-CoV-2 hepatitis early after liver transplantation. Pediatr Transplant. 2020;24(8):e13778.
27. Godfred-Cato S, Bryant B, Leung J, et al. COVID-19-associated multisystem inflammatory syndrome in children - United States, March-July 2020. MMWR Morb Mortal Wkly Rep. 2020;69(32):1074-1080.
28. Consiglio CR, Cotugno N, Sardh F, et al. The immunity of multisystem inflammatory syndrome in children with COVID-19. Cell. 2020;183(4):968-981.
29. Chen Y, Fan C, Chen Y, et al. Effect of hepatic steatosis on the progression of chronic hepatitis B: a prospective cohort and in vitro study. Oncotarget. 2017;8(35):58601-58610.
30. Hussain A, Mahawar K, Xia Z, Yang W, El-Hasani S. Obesity and mortality of COVID-19. Meta-analysis. Obes Res Clin Pract. 2020;14(4):295-300.
31. Maurya R, Bhattacharya P, Dey R, Nakhasi HL. Leptin functions in infectious diseases. Front Immunol. 2018;9:2741.
32. Rojas-Osorio SA, Cruz-Hernández TR, Drago-Serrano ME, Campos-Rodríguez R. Immunity to influenza: impact of obesity. Obes Res Clin Pract. 2019;13(5):419-429.
33. Skinner AC, Ravanbakht SN, Skelton JA, Perrin EM, Armstrong SC. Prevalence of obesity and severe obesity in US children, 1999–2016. Pediatrics. 2018;141(3):1999-2016.
34. Webb Hooper M, Nápoles AM, Pérez-Stable EJ. COVID-19 and racial/ethnic disparities. JAMA. 2020;323(24):2466-2467.
35. Lee EH, Kepler KL, Gevarughese A, et al. Race/ethnicity among children with COVID-19-associated multisystem inflammatory syndrome. JAMA Netw Open. 2020;3(11):e2030280.

**SUPPORTING INFORMATION**

Additional supporting information may be found online in the Supporting Information section.

How to cite this article: Perez A, Cantor A, Rudolph B, et al. Liver involvement in children with SARS-COV-2 infection: Two distinct clinical phenotypes caused by the same virus. Liver Int. 2021;00:1–8. https://doi.org/10.1111/liv.14887